ALNYLAM PHARMACEUTICALS, INC. Earnings Per Share (Basic)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Earnings Per Share (Basic) of $1.23 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-06-30 was $1.23.
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-12-31 was $0.84.
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-09-30 was $1.91.
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$0.55.
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2025 was $2.39.
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2024 was -$2.18.
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2023 was -$3.52.
- ALNYLAM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2022 was -$9.30.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.23 10-Q · filed 2026-07-30 | $2.78 10-Q · filed 2026-07-30 | |||||
| 2025-12-31 | $0.84 derived: net income ÷ weighted average shares · filed 2026-04-06 | $2.75 derived: net income ÷ weighted average shares · filed 2026-04-06 | $2.21 derived: net income ÷ weighted average shares · filed 2026-07-30 | $2.39 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $1.91 10-Q · filed 2025-10-30 | $1.36 derived: net income ÷ weighted average shares · filed 2026-07-30 | $1.55 10-K · filed 2026-02-12 | $0.98 10-Q · filed 2025-10-30 | $0.59 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2025-06-30 | -$0.55 10-Q · filed 2026-07-30 | -$0.51 10-Q · filed 2025-07-31 | -$0.70 10-Q · filed 2026-07-30 | -$0.95 10-Q · filed 2025-07-31 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$2.21 derived: net income ÷ weighted average shares · filed 2026-07-30 | |
| 2025-03-31 | -$0.14 10-K · filed 2026-02-12 | -$0.44 10-Q · filed 2025-05-01 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$1.65 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2024-12-31 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$1.66 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$2.18 10-K · filed 2026-02-12 | |||
| 2024-09-30 | -$0.87 10-Q · filed 2025-10-30 | -$1.01 derived: net income ÷ weighted average shares · filed 2025-10-30 | -$1.53 10-Q · filed 2025-10-30 | -$2.62 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2024-06-30 | -$0.13 10-Q · filed 2025-07-31 | -$0.66 10-Q · filed 2025-07-31 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2024-03-31 | -$0.52 10-Q · filed 2025-05-01 | -$1.62 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$2.65 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2023-12-31 | -$1.10 derived: net income ÷ weighted average shares · filed 2026-04-06 | $0.08 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$2.13 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$3.52 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $1.18 10-Q · filed 2024-10-31 | -$1.03 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$2.43 10-Q · filed 2024-10-31 | -$4.10 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2023-06-30 | -$2.21 10-Q · filed 2024-08-01 | -$3.62 10-Q · filed 2024-08-01 | -$5.30 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$8.61 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2023-03-31 | -$1.40 10-Q · filed 2024-05-02 | -$3.08 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$6.39 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$8.69 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2022-12-31 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$5.00 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$7.29 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$9.30 10-K · filed 2025-02-13 | |||
| 2022-09-30 | -$3.32 10-Q · filed 2023-11-02 | -$5.62 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$7.62 10-Q · filed 2023-11-02 | -$9.78 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2022-06-30 | -$2.29 10-Q · filed 2023-08-03 | -$4.29 10-Q · filed 2023-08-03 | -$6.45 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$8.17 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2022-03-31 | -$2.00 10-Q · filed 2023-05-04 | -$4.15 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$5.87 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$7.49 derived: net income ÷ weighted average shares · filed 2026-04-06 | |||
| 2021-12-31 | -$2.16 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$3.88 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$5.49 derived: net income ÷ weighted average shares · filed 2026-04-06 | -$7.20 10-K · filed 2024-02-15 | |||
| 2021-09-30 | -$1.72 10-Q · filed 2022-10-27 | -$3.33 derived: net income ÷ weighted average shares · filed 2022-10-27 | -$5.04 10-Q · filed 2022-10-27 | -$7.13 derived: net income ÷ weighted average shares · filed 2023-02-23 | |||
| 2021-06-30 | -$1.61 10-Q · filed 2022-07-28 | -$3.32 10-Q · filed 2022-07-28 | -$5.41 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$7.59 derived: net income ÷ weighted average shares · filed 2023-02-23 | |||
| 2021-03-31 | -$1.71 10-Q · filed 2022-04-28 | -$3.80 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$5.99 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$7.55 derived: net income ÷ weighted average shares · filed 2023-02-23 | |||
| 2020-12-31 | -$2.09 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$4.28 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$5.84 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$7.46 10-K · filed 2023-02-23 | |||
| 2020-09-30 | -$2.18 10-Q · filed 2021-10-28 | -$3.75 derived: net income ÷ weighted average shares · filed 2021-10-28 | -$5.37 10-Q · filed 2021-10-28 | ||||
| 2020-06-30 | -$1.56 10-Q · filed 2021-08-03 | -$3.18 10-Q · filed 2021-08-03 | |||||
| 2019-12-31 | -$8.11 10-K · filed 2022-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |